Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
MDS Foundation: Significant advances made in understanding, treating MDS, AML

MDS Foundation: Significant advances made in understanding, treating MDS, AML

Mitoxantrone increases survival for children with relapsed ALL, trial results show

Mitoxantrone increases survival for children with relapsed ALL, trial results show

SAGE launches two new journals in Drug Safety, Hematology

SAGE launches two new journals in Drug Safety, Hematology

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium presents results from cancer stem cell program at ASH Annual Meeting

New clue in leukemia mystery

New clue in leukemia mystery

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

LMO1 gene variation can increase neuroblastoma risk

LMO1 gene variation can increase neuroblastoma risk

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University enrolls first U.S. patient in international clinical trial for melanoma

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

Overexpression of microRNA 125b can cause leukemia: Research

Overexpression of microRNA 125b can cause leukemia: Research

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

JAK3 pathway highlighted as leukemia target

JAK3 pathway highlighted as leukemia target

Elbit Imaging closes transaction with Enter

Elbit Imaging closes transaction with Enter

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Cord Blood America shares web site post on Thanksgiving Day

Cord Blood America shares web site post on Thanksgiving Day

Researchers identify trigger mechanism for quality control checkpoint in cell division process

Researchers identify trigger mechanism for quality control checkpoint in cell division process

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.